and supporting this as being defined a u201c no effect u201d dose level however over the 18 months follow up period a small gradual increase in the c peptide glucose ratio was seen this was however not statistically significant a steady gradual increase in hba 1c levels p 0 01 was found in the placebo but not in the other dose groups inferring a reduction in glycemic control as diabetes progressed in untreated patients through the 18 months study period a greater trend towards elevated hba 1c levels was indicated for the placebo 4 u03bcg dose group than for the 100 u03bcg dose group suggesting in contrast an improvement in glycemic control in patients receiving the latter dose level in the 20 u03bcg dose group in particular a decrease in hba 1c levels was seen throughout the 18 month follow up period indicating an improvement in glycemic control the average rate of change in hba 1c per month was statistically significant compared to placebo in the 20 u03bcg dose group p20 01 which was estimated by a linear mixed model assuming random intercepts and slopes no significant change in gad65ab levels expressed as u ml was found in the placebo.